Truist Securities Maintains Hold on Inari Medical, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Hold rating on Inari Medical while raising the price target from $46 to $50.
October 29, 2024 | 5:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has maintained a Hold rating on Inari Medical and increased the price target from $46 to $50, indicating a positive outlook.
The increase in price target from $46 to $50 by Truist Securities suggests a positive outlook for Inari Medical. Although the Hold rating remains, the raised target indicates potential for stock appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100